XOStem Revenue and Competitors

XOStem is on the leading edge of translational biochemistry, using our Stem Cell expertise to create the next generation treatment for Type 1 Diabetes and produce Engineered Exosomes. Our combination of commercially developed science, partnerships with key scientific institutions, and university validation, enables us to rapidly bring to market novel therapies to tangibly improve people’s lives. More applications utilizing our Stem Cell technology will follow. Our engineered exosome science is bringing to market the next generation of exosomes for regenerative skin care, joint care, and other therapies. Our research, technology and assays encompass the best methods for exosome isolation, purity, and characterization. More importantly our science leads the new frontier of engineered exosomes that carry well-defined payloads for more successful outcomes. Our bioscience device will contain insulin producing cells similar to islets found in a healthy pancreas. Our unique encapsulation technology protects our cells from the autoimmune attack that killed the islets in the patient’s pancreas. Our device eliminates the pricking, needles, sensors and ports used by traditional insulin injection. Existing therapies for type 1 diabetes patients inject insulin using manual or automated methods, attempting to emulate pancreatic islet production of insulin. While better methods for monitoring and injection have been attempted, many drawbacks exist, and none control blood sugar levels to the tight level of natural islets. More importantly, the micro encapsulated islets combined with our macro device will control blood sugar levels to the same levels of a normal pancreas, minimizing the likelihood of the dreaded diabetes complications. Our team has decades of experience refining our technology in the laboratory, we are now moving to alleviate type 1 diabetes in companion animals (Dogs and Cats), once our process has significant successful data, we will then move to humans.